Literature DB >> 29997084

[Generation of a new strain of NOD/SCID/IL2Rγ-/- mice with targeted disruption of Prkdc and IL2Rγ genes using CRISPR/Cas9 system].

Ya-Chen Liu1, Qu Chen, Xing-Long Yang, Qing-Shuang Tang, Kai-Tai Yao, Yang Xu.   

Abstract

OBJECTIVE: The NOD/SCID/IL2Rγ- /- (NSG) mouse strain is the most widely used immunodeficient strain for xenograft transplantation. However, the existing SCID mutation is a spontaneous mutation of the Prkdc gene, which leads to leaky T cell developmental block and difficulty in genotyping. It is therefore important to develop a new strain of NSG mice with targeted disruption of Prkdc and IL2Rγ genes.
METHODS: Targeted disruption of Prkdc and IL2Rγ genes was achieved using the CRISPR/Cas9 system. By intercrossing the knockout and NOD mice, we obtained a novel strain of NOD/SCID/IL2Rγ- /-(NSG) mice, denoted as cNSG (Chinese NSG) mice.
RESULTS: In addition to the NOD mutation, cNSG mice exhibited a complete absence of T cells, B cells and NK cells. cNSG mice allowed more efficient engraftment of human cancer cells than the commonly used immunodeficient nude mice.
CONCLUSION: cNSG mice will provide an important xenotransplantation model for biomedical research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29997084      PMCID: PMC6765701     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  24 in total

1.  Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice.

Authors:  S W Christianson; D L Greiner; R A Hesselton; J H Leif; E J Wagar; I B Schweitzer; T V Rajan; B Gott; D C Roopenian; L D Shultz
Journal:  J Immunol       Date:  1997-04-15       Impact factor: 5.422

2.  Knockout mice created by TALEN-mediated gene targeting.

Authors:  Young Hoon Sung; In-Jeoung Baek; Duk Hyoung Kim; Jisun Jeon; Jaehoon Lee; Kyunghee Lee; Daewon Jeong; Jin-Soo Kim; Han-Woong Lee
Journal:  Nat Biotechnol       Date:  2013-01       Impact factor: 54.908

3.  Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment.

Authors:  Takuji Yamauchi; Katsuto Takenaka; Shingo Urata; Takahiro Shima; Yoshikane Kikushige; Takahito Tokuyama; Chika Iwamoto; Mariko Nishihara; Hiromi Iwasaki; Toshihiro Miyamoto; Nakayuki Honma; Miki Nakao; Takashi Matozaki; Koichi Akashi
Journal:  Blood       Date:  2013-01-04       Impact factor: 22.113

4.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

5.  RAG-1-deficient mice have no mature B and T lymphocytes.

Authors:  P Mombaerts; J Iacomini; R S Johnson; K Herrup; S Tonegawa; V E Papaioannou
Journal:  Cell       Date:  1992-03-06       Impact factor: 41.582

6.  RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement.

Authors:  Y Shinkai; G Rathbun; K P Lam; E M Oltz; V Stewart; M Mendelsohn; J Charron; M Datta; F Young; A M Stall
Journal:  Cell       Date:  1992-03-06       Impact factor: 41.582

7.  A severe combined immunodeficiency mutation in the mouse.

Authors:  G C Bosma; R P Custer; M J Bosma
Journal:  Nature       Date:  1983-02-10       Impact factor: 49.962

8.  Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain.

Authors:  X Cao; E W Shores; J Hu-Li; M R Anver; B L Kelsall; S M Russell; J Drago; M Noguchi; A Grinberg; E T Bloom
Journal:  Immunity       Date:  1995-03       Impact factor: 31.745

9.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice.

Authors:  L D Shultz; P A Schweitzer; S W Christianson; B Gott; I B Schweitzer; B Tennent; S McKenna; L Mobraaten; T V Rajan; D L Greiner
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

10.  One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering.

Authors:  Haoyi Wang; Hui Yang; Chikdu S Shivalila; Meelad M Dawlaty; Albert W Cheng; Feng Zhang; Rudolf Jaenisch
Journal:  Cell       Date:  2013-05-02       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.